News Releases

Date	Title and Summary	View
Oct 01, 2020	Johnson & Johnson Completes Acquisition of Momenta Pharmaceuticals, Inc. Acquisition broadens Janssen's leadership in autoimmune diseases and provides a major catalyst for sustained growth NEW BRUNSWICK, N.J. , Oct. 1, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced it has successfully completed its acquisition of Momenta Pharmaceuticals, Inc.
Sep 30, 2020	SIMPONI ARIA® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
Sep 30, 2020	Janssen Submits New Drug Application (NDA) to U.S. FDA for UPTRAVI® (selexipag) Injection for Intravenous Use to Treat Pulmonary Arterial Hypertension (PAH)
Sep 23, 2020	Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssen's COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S NEW BRUNSWICK, N.J. , Sept. 23, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its
Sep 20, 2020	Janssen Presents Findings from Global, Multi-Center Trial Examining Amivantamab in Combination with Lazertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
Sep 14, 2020	Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
Sep 14, 2020	Janssen to Present Key Data from Across Its Expansive Oncology Portfolio at ESMO 2020 Virtual Congress
Sep 11, 2020	Janssen Highlights Impact of Multiple Sclerosis-Related Fatigue with Real-World Study Data Presentation at MSVirtual2020 and Global Patient Survey
Sep 10, 2020	Janssen Submits Application Seeking U.S. FDA Approval of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) for the Treatment of Patients with Light Chain (AL) Amyloidosis
Sep 10, 2020	Health Canada Approves TREMFYA®* (guselkumab injection), a First-In-Class Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis